AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Zai Lab: to await results of Fortitude-102 prior to reg. filing
ByAinvest
Wednesday, Sep 3, 2025 10:44 am ET1min read
Zai Lab: to await results of Fortitude-102 prior to reg. filing
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative biopharmaceutical company based in China and the United States, has announced that it will await the results of its Fortitude-102 trial before submitting a regulatory filing. The company has scheduled key presentations at upcoming investor conferences in September 2025, providing an opportunity for investors to stay informed about Zai Lab's progress and future plans.On Thursday, September 4, 2025, at 10:20 a.m. ET, members of Zai Lab's senior management team will present at the Cantor Global Healthcare Conference in New York, NY [1]. Additionally, on Tuesday, September 9, 2025, at 2:35 p.m. ET, Zai Lab will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference, also in New York, NY. Live webcasts and archived replays of these events will be available on Zai Lab's Investor Relations page at ir.zailaboratory.com/webcasts-presentations and will be accessible for up to 90 days following the events [1].
Zai Lab's focus is on discovering, developing, and commercializing innovative products that address significant unmet medical needs in the areas of oncology, immunology, neuroscience, and infectious disease. The company's decision to await the Fortitude-102 trial results before filing for regulatory approval reflects its commitment to rigorous scientific standards and patient safety.
For more information about Zai Lab and its upcoming events, please visit www.zailaboratory.com or follow them at www.X.com/ZaiLab_Global. Contact details for investor relations and media inquiries are also available on the company's website [1].
References:
[1] https://www.biospace.com/press-releases/zai-lab-announces-participation-in-investor-conferences-in-september-2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet